Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes

May 2013

Reps will promote Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes.

You'll hear it referred to as an "SGLT2 inhibitor"...because it inhibits sodium-glucose co-transporter 2 in the kidneys. This allows more glucose to spill into the urine instead of being reabsorbed.

Reps will point out that Invokana reduces A1C by 1% when used alone...and it has a low risk of hypoglycemia.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Administration buzz about a new report called Choosing Wisely
Travel Medicine Patients often ask how they can stay healthy while traveling
Smoking whether electronic cigarettes or hookah pipes are safer than smoking cigarettes
Shortages doxycycline AND tetracycline are in short supply
Cardiology Many more patients will now ask about the Mediterranean diet
Pediatrics how to treat anxiety in kids
Antithrombotics whether to stop antithrombotics for MINOR surgical procedures or endoscopy
Diabetes Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes
Fungal Infections how to get rid of fungal nail infections
Gastroenterology strike a balance between the risks and benefits of use of PPIs for gastroesophageal reflux disease (GERD)

Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents